3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 2
2
Phase 1/2
2
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Leukemia, Myeloid, Acute
34
Leukemia
26
Lymphoma, Non-Hodgkin
23
Lymphoma
22
Precursor Cell Lymphoblastic Leukemia-Lymphoma
21
Recurrence
19
Leukemia, Lymphocytic, Chronic, B-Cell
19
Myelodysplastic Syndromes
18
Hematologic Neoplasms
18
Melanoma
16
Neoplasm Metastasis
15
Lymphoma, B-Cell
14
Multiple Myeloma
12
Pancreatic Neoplasms
11
Hodgkin Disease
11
Stomach Neoplasms
10
Ovarian Neoplasms
10
Lymphoma, Large B-Cell, Diffuse
10
Breast Neoplasms
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Lymphoma, Mantle-Cell
7
Lymphoma, Follicular
7
Uterine Cervical Neoplasms
6
Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Triple Negative Breast Neoplasms
5
Neoplasms, Plasma Cell
5
Kidney Neoplasms
5
Burkitt Lymphoma
5
Myeloproliferative Disorders
4
Interventions
Sorafenib
7
Radiosurgery
6
Bevacizumab
6
pembrolizumab
4
Oxaliplatin
4
Cryosurgery
4
atezolizumab
3
Radiotherapy, Conformal
3
Nivolumab
3
Ipilimumab
3
Fluorouracil
3
Cyclophosphamide
3
tremelimumab
2
spartalizumab
2
lenvatinib
2
fludarabine
2
Leucovorin
2
Injections
2
Gemcitabine
2
Everolimus
2
Epirubicin
2
Doxorubicin
2
Celecoxib
2
Carboplatin
2
Capecitabine
2
yttrium chloride
1
vofatamab
1
toripalimab
1
tocilizumab
1
sapanisertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Liver Neoplasms
×
fludarabine
×
Clear all
NCT07500220
2026-03-30
DUET-HCC
Beijing Biotech
Phase 1/2
Recruiting
30 enrolled
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled